Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | RXRG | P48443 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10233498 | 0.83 | CYP2A6 (0.45) | RXRARXRGCYP2A6KIF11CTSS | |
| SCHEMBL17319636 | 0.83 | RXRA (0.47) | RXRARXRGKIF11MRGPRX4L3MBTL1 | |
| SCHEMBL18255653 | 0.82 | LOXL2 (0.47) | RXRARXRGKIF11MRGPRX4L3MBTL1 | |
| SCHEMBL16957815 | 0.81 | IDO1 (0.36) | RXRARXRGIDO1TACR1 | |
| SCHEMBL129227 | 0.81 | RXRA (0.49) | RXRARXRGKIF11MRGPRX4L3MBTL1 | |
| SCHEMBL24108532 | 0.81 | RXRA (0.46) | RXRARXRGKIF11MRGPRX4L3MBTL1 | |
| SCHEMBL130428 | 0.81 | RXRA (0.46) | RXRARXRGKIF11MRGPRX4L3MBTL1 | |
| SCHEMBL169517 | 0.81 | RXRA (0.46) | RXRARXRGKIF11MRGPRX4L3MBTL1 | |
| SCHEMBL2390020 | 0.81 | RXRA (0.49) | RXRARXRGKIF11MRGPRX4L3MBTL1 | |
| SCHEMBL29812995 | 0.81 | RXRA (0.46) | RXRARXRGKIF11MRGPRX4L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002364-A1 | BENZOTHIOPHENE DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
| US-20210395217-A1 | PESTICIDALLY ACTIVE AZOLE-AMIDE COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2021-12-23 | — | — | US | disclosed |
| US-20120258986-A1 | OLEFIN CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| EP-1730152-B1 | TETRAHYDROQUINOLINE DERIVATIVES AND A PROCESS FOR PREPARING THE SAME | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-8158640-B2 | Tetrahydroquinoline derivatives and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-04-17 | — | — | US | disclosed |
| US-8158640-B2 | Tetrahydroquinoline derivatives and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-04-17 | — | — | US | disclosed |
| EP-1979331-B1 | TRISUBSTITUTED AMINE COMPOUNDS AS INHIBITORS OF -CHOLESTERYL ESTER TRANSFER PROTEIN CETP | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-8076364-B2 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-12-13 | — | — | US | disclosed |
| US-8076364-B2 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-12-13 | — | — | US | disclosed |
| US-20110092506-A1 | TRISUBSTITUTED AMINE COMPOUND | NAKAMURA YOSHINORI | 2011-04-21 | — | — | US | disclosed |
| US-20090029994-A1 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-29 | — | — | US | disclosed |
| US-20090029994-A1 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-29 | — | — | US | disclosed |
| US-20090023729-A1 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-22 | — | — | US | disclosed |
| US-20090023729-A1 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-22 | — | — | US | disclosed |
| WO-2007088996-A1 | TRISUBSTITUTED AMINE COMPOUNDS AS INHIBITORS OF -CHOLESTERYL ESTER TRANSFER PROTEIN CETP | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007088999-A1 | TRISUBSTITUTED AMINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | WO | disclosed |
| US-20070082896-A1 | Tetrahydroquinoline derivatives and a process for preparing the same | TANABE SEIYAKU CO., LTD. | 2007-04-12 | — | — | US | disclosed |
| US-20070082896-A1 | Tetrahydroquinoline derivatives and a process for preparing the same | TANABE SEIYAKU CO., LTD. | 2007-04-12 | — | — | US | disclosed |
| US-20070032485-A1 | Tetrahydronaphthyridine derivatives and a process for preparing the same | TANABE SEIYAKU CO., LTD. | 2007-02-08 | — | — | US | disclosed |
| US-20070032485-A1 | Tetrahydronaphthyridine derivatives and a process for preparing the same | TANABE SEIYAKU CO., LTD. | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092506-A1 | TRISUBSTITUTED AMINE COMPOUND | CETP, MTTP, APOB | RXRA 4140/4885RXRG 3924/4885CYP2A6 1237/4885 |
| US-20070082896-A1 | Tetrahydroquinoline derivatives and a process for preparing the same | CETP, MTTP, NPC1L1 | RXRA 2833/4885RXRG 2501/4885CYP2A6 2003/4885 |
| US-20210395217-A1 | PESTICIDALLY ACTIVE AZOLE-AMIDE COMPOUNDS | DDT, ACHE, CYP51A1 | RXRA 3093/4885RXRG 3012/4885CYP2A6 388/4885 |
| US-20070032485-A1 | Tetrahydronaphthyridine derivatives and a process for preparing the same | CETP, MTTP, NPC1L1 | RXRA 2242/4885RXRG 2255/4885CYP2A6 2308/4885 |
| US-20090029994-A1 | Trisubstituted amine compound | CETP, MTTP, APOB | RXRA 4140/4885RXRG 3924/4885CYP2A6 1237/4885 |
| US-20120258986-A1 | OLEFIN CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | NXF1, NCOA1, XPO1 | RXRA 1911/4885RXRG 1645/4885CYP2A6 2622/4885 |
| US-20230002364-A1 | BENZOTHIOPHENE DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | GPER1, GABRQ, GPR39 | RXRA 2779/4885RXRG 2428/4885CYP2A6 960/4885 |
| US-20090023729-A1 | Trisubstituted amine compound | CETP, MTTP, APOB | RXRA 3987/4885RXRG 3783/4885CYP2A6 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.